hVIVO Mannheim
Mannheim, 68167, Germany
Location status: Recruiting
NCT Number: NCT07754474
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related co-morbidity following subcutaneous administration.
Interested in participating?
Request Info18 year–74 year
All sexes
Interventional
Phase 1
Mannheim, 68167, Germany
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI 3034701
Placebo
Time frame: Up to 113 days
Time frame: Up to 106 days
Time frame: Up to 106 days
Contact information is provided by the study sponsor or research team.
Boehringer Ingelheim
Industry
A Phase I, Randomized, Single-blind, Parallel-group Trial for BI 3034701 Compared to Placebo in Participants With Overweight / Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07803744
Autoimmune Diseases, Body Weight
Miami, Florida, United States
View Trial DetailsNCT07369011
Apnea, Body Weight
Cullman, Alabama, United States
View Trial DetailsNCT07321886
Body Weight, Nutrition Disorders
Tuscaloosa, Alabama, United States
View Trial DetailsNCT07037433
Arterial Occlusive Diseases, Arteriosclerosis
Daphne, Alabama, United States
View Trial Details